Data demonstrated proof-of-concept for berobenatide as a first-in-class monthly GLP-1 RA peptide with competitive weight loss ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

The natural GLP-1 hormone survives in the body for only a few minutes before it is broken down. Drug developers overcome this ...

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...

The pharmaceutical corporation Pfizer announced Tuesday that its experimental weight loss jab showed solid results when taken monthly during an ongoing mid-stage clinical trial. And there was no ...

Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...

In a major but expected change, pharmaceutical manufacturing giant Pfizer has announced that it will expand the ability of outside researchers and patients enrolled in its clinical trials to access ...